ETFs positioned on Ipsen

Name YTD change Weight AuM
+12.91%-.--% 27,154 M€
+8.55%-.--% 92 M€
+14.82%-.--% 13 M€
+6.41%-.--% 49 M€
+1.90%-.--% 51 M€
+12.33%-.--% 66 M€
+13.45%-.--% 24,432 M€
+8.93%-.--% 75 M€
+11.14%-.--% 67 M€
+12.45%-.--% 6 M€
+11.49%-.--% 1,193 M€
+13.28%-.--% 6,576 M€
+13.23%-.--% 3,469 M€
+14.85%-.--% 5,871 M€
0.00%4.67% 8 M€
+58.38%3.96% 215 M€
+18.00%3.25% 23 M€
+15.00%1.94% 31 M€
+8.58%1.94% 31 M€
+8.64%1.75% 574 M€
+12.81%1.54% 18 M€
+14.54%1.52% 17 M€
+14.59%1.48% 160 M€
0.00%1.05% 208 M€
0.00%1.05% 26 M€
+11.56%0.98% 125 M€
+11.60%0.87% 730 M€
+9.67%0.83% 55 M€
+9.43%0.83% 20 M€
+20.58%0.79% 1,260 M€
+14.22%0.78% 103 M€
+12.72%0.59% 140 M€
+5.83%0.58% 38 M€
+10.78%0.54% 51 M€
+11.90%0.53% 40 M€
+10.67%0.5% 23 M€
+14.10%0.47% 937 M€
Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
166.00EUR
Average target price
167.07EUR
Spread / Average Target
+0.64%

Quarterly revenue - Rate of surprise